NVNO: enVVeno Medical Corporation Stock

by  •  • Comments Off on NVNO: enVVeno Medical Corporation Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 47.96
Enterprise Value ($M) 46.21
Book Value ($M) 42.16
Book Value / Share 2.40
Price / Book 1.14
NCAV ($M) 40.94
NCAV / Share 2.33
Price / NCAV 1.17

Profitability (mra)
Return on Invested Capital (ROIC) -0.50
Return on Assets (ROA) -0.49
Return on Equity (ROE) -0.51

Liquidity (mrq)
Quick Ratio 20.88
Current Ratio 20.88

Balance Sheet (mrq) ($M)
Current Assets 43.73
Assets 44.95
Liabilities 2.79
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -23.83
Net Income -21.82
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -16.84
Cash from Investing 1.33
Cash from Financing 13.64

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Nantahala Capital Management, LLC 7.06 -8.13
11-14 13G/A Perceptive Advisors Llc 9.90 34.02

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13
2025-02-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 1
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SE
2024-07-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTIO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-28 14,253 41,327 34.49
2025-04-25 5,281 47,887 11.03
2025-04-24 6,245 21,953 28.45
2025-04-23 9,451 43,876 21.54

(click for more detail)

Similar Companies
NTRB – Nutriband Inc. NURO – NeuroMetrix, Inc.
NUWE – Nuwellis, Inc. NXGL – NEXGEL, Inc.
NXL – Nexalin Technology, Inc.


Financial data and stock pages provided by
Fintel.io